Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The TELEX trial will establish whether telmisartan alone improves walking performance in
people with peripheral artery disease (PAD). The TELEX trial will also determine whether
telmisartan plus supervised exercise improves walking performance more than either therapy
alone. TELEX is a randomized controlled clinical trial (2 x 2 factorial design) of 112
participants with PAD randomized to one of four arms: Group A: telmisartan + supervised
exercise therapy; Group B: telmisartan + a "no exercise" control group; Group C: placebo +
supervised exercise therapy; and Group D: placebo + a "no exercise" control group.